Meeting
2018 ASCO Annual Meeting
A phase I study of palbociclib (PALBO) plus everolimus (EVE) and exemestane (EXE) in hormone-receptor positive (HR+)/HER2- metastatic breast cancer (MBC) after progression on a CDK4/6 inhibitor (CDK4/6i): safety, tolerability and pharmacokinetic (PK) analysis.
Authors
Romualdo Barroso-Sousa
Dana-Farber Cancer Institute, Boston, MA
Romualdo Barroso-Sousa , Hao Guo , William Thomas Barry , Arlindo R. Ferreira , Rebecca Rees , Eric P. Winer , Nikhil Wagle , Sara M. Tolaney
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Breast Cancer—Metastatic
Track
Breast Cancer
Sub Track
Hormone Receptor-Positive
Clinical Trial Registration Number
02871791
Citation
J Clin Oncol 36, 2018 (suppl; abstr 1068)
DOI
10.1200/JCO.2018.36.15_suppl.1068
Abstract #
1068
Poster Bd #
149
Abstract Disclosures
Similar Posters
Poster
2019 ASCO Annual Meeting
Triplet therapy (continuous ribociclib, everolimus, exemestane) in HR+/HER2− advanced breast cancer postprogression on a CDK4/6 inhibitor (TRINITI-1): Efficacy, safety, and biomarker results.
First Author: Aditya Bardia
Poster
2018 ASCO Annual Meeting
Phase Ib study of gedatolisib in combination with palbociclib and endocrine therapy (ET) in women with estrogen receptor (ER) positive (+) metastatic breast cancer (MBC) (B2151009).
First Author: Andres Forero-Torres
Poster
2023 ASCO Annual Meeting
A phase 1b/2 dose escalation and expansion study of OP-1250 in combination with ribociclib or alpelisib in patients with advanced and/or metastatic estrogen receptor–positive (ER+)/HER2-negative (HER2-) breast cancer.
First Author: Virginia F. Borges
Poster
2023 ASCO Annual Meeting
First-in-human phase 1 dose escalation study of the KAT6 inhibitor PF-07248144 in patients with advanced solid tumors.
First Author: David Sommerhalder